Tissue | Expression Dynamics | Abbreviation |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/DLC1_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/DLC1_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/DLC1_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/DLC1_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/DLC1_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00512716 | Oral cavity | EOLP | negative regulation of cellular component movement | 67/2218 | 367/18723 | 1.97e-04 | 2.00e-03 | 67 |
GO:00309005 | Oral cavity | EOLP | forebrain development | 68/2218 | 379/18723 | 2.97e-04 | 2.79e-03 | 68 |
GO:20001466 | Oral cavity | EOLP | negative regulation of cell motility | 65/2218 | 359/18723 | 3.09e-04 | 2.89e-03 | 65 |
GO:005101726 | Oral cavity | EOLP | actin filament bundle assembly | 33/2218 | 157/18723 | 7.04e-04 | 5.78e-03 | 33 |
GO:003103218 | Oral cavity | EOLP | actomyosin structure organization | 39/2218 | 196/18723 | 7.64e-04 | 6.12e-03 | 39 |
GO:0061572110 | Oral cavity | EOLP | actin filament bundle organization | 33/2218 | 161/18723 | 1.11e-03 | 8.11e-03 | 33 |
GO:00400136 | Oral cavity | EOLP | negative regulation of locomotion | 67/2218 | 391/18723 | 1.17e-03 | 8.47e-03 | 67 |
GO:000726615 | Oral cavity | EOLP | Rho protein signal transduction | 29/2218 | 137/18723 | 1.28e-03 | 9.16e-03 | 29 |
GO:19018889 | Oral cavity | EOLP | regulation of cell junction assembly | 39/2218 | 204/18723 | 1.67e-03 | 1.11e-02 | 39 |
GO:0030038110 | Oral cavity | EOLP | contractile actin filament bundle assembly | 23/2218 | 106/18723 | 2.78e-03 | 1.66e-02 | 23 |
GO:0043149110 | Oral cavity | EOLP | stress fiber assembly | 23/2218 | 106/18723 | 2.78e-03 | 1.66e-02 | 23 |
GO:005149416 | Oral cavity | EOLP | negative regulation of cytoskeleton organization | 31/2218 | 163/18723 | 5.09e-03 | 2.67e-02 | 31 |
GO:00510569 | Oral cavity | EOLP | regulation of small GTPase mediated signal transduction | 51/2218 | 302/18723 | 5.67e-03 | 2.92e-02 | 51 |
GO:000691921 | Oral cavity | EOLP | activation of cysteine-type endopeptidase activity involved in apoptotic process | 17/2218 | 78/18723 | 8.89e-03 | 4.12e-02 | 17 |
GO:0051492110 | Oral cavity | EOLP | regulation of stress fiber assembly | 19/2218 | 91/18723 | 9.46e-03 | 4.29e-02 | 19 |
GO:0032231110 | Oral cavity | EOLP | regulation of actin filament bundle assembly | 21/2218 | 105/18723 | 1.08e-02 | 4.80e-02 | 21 |
GO:003158932 | Oral cavity | NEOLP | cell-substrate adhesion | 93/2005 | 363/18723 | 4.93e-16 | 2.93e-13 | 93 |
GO:000704424 | Oral cavity | NEOLP | cell-substrate junction assembly | 40/2005 | 95/18723 | 2.83e-15 | 1.29e-12 | 40 |
GO:015011532 | Oral cavity | NEOLP | cell-substrate junction organization | 41/2005 | 101/18723 | 5.88e-15 | 2.50e-12 | 41 |
GO:005189323 | Oral cavity | NEOLP | regulation of focal adhesion assembly | 30/2005 | 66/18723 | 7.33e-13 | 1.89e-10 | 30 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
DLC1 | SNV | Missense_Mutation | | c.2960N>C | p.Gly987Ala | p.G987A | Q96QB1 | protein_coding | deleterious(0) | possibly_damaging(0.449) | TCGA-A2-A0D0-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
DLC1 | SNV | Missense_Mutation | rs773001160 | c.1724G>A | p.Gly575Asp | p.G575D | Q96QB1 | protein_coding | deleterious(0.04) | benign(0.018) | TCGA-A8-A092-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | CR |
DLC1 | SNV | Missense_Mutation | rs762750959 | c.1723G>A | p.Gly575Ser | p.G575S | Q96QB1 | protein_coding | tolerated(0.28) | benign(0) | TCGA-A8-A092-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | CR |
DLC1 | SNV | Missense_Mutation | | c.2533N>A | p.Gly845Ser | p.G845S | Q96QB1 | protein_coding | tolerated(0.11) | probably_damaging(1) | TCGA-A8-A09Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
DLC1 | SNV | Missense_Mutation | novel | c.4058N>G | p.Glu1353Gly | p.E1353G | Q96QB1 | protein_coding | deleterious(0) | benign(0.41) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
DLC1 | SNV | Missense_Mutation | | c.3983N>T | p.Cys1328Phe | p.C1328F | Q96QB1 | protein_coding | tolerated(0.15) | possibly_damaging(0.803) | TCGA-AO-A03V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | fluorouracil | SD |
DLC1 | SNV | Missense_Mutation | | c.305C>A | p.Ala102Asp | p.A102D | Q96QB1 | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.905) | TCGA-AO-A124-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
DLC1 | SNV | Missense_Mutation | | c.3205N>C | p.Asp1069His | p.D1069H | Q96QB1 | protein_coding | deleterious(0) | benign(0.354) | TCGA-C8-A26Y-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
DLC1 | SNV | Missense_Mutation | | c.2882N>A | p.Pro961His | p.P961H | Q96QB1 | protein_coding | deleterious(0.02) | possibly_damaging(0.525) | TCGA-D8-A1JF-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
DLC1 | SNV | Missense_Mutation | rs745492706 | c.878N>A | p.Gly293Asp | p.G293D | Q96QB1 | protein_coding | tolerated_low_confidence(0.35) | benign(0.001) | TCGA-D8-A1XF-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin+cyclophosphamide | SD |